Global Human Growth Hormone (HGH) Market Report by Application, Distribution Channel, Route of Administration, Countries and Company Analysis, 2026-2034

Global Human Growth Hormone (HGH) Market Size and Forecast 2026-2034

Human Growth Hormone (HGH) Market is expected to reach US$ 18.57 Billion by 2034 from US$ 7.8 Billion in 2025, with a CAGR of 10.12% from 2026 to 2034. The Human Growth Hormone (HGH) Market comprises recombinant growth hormone therapies used primarily to treat growth hormone deficiency and selected growth-related disorders. Market development is supported by improved diagnosis, pediatric endocrinology, long-acting formulations, and expanding access to specialized hormone therapies.

Human Growth Hormone (HGH) Industry Overview

Human Growth Hormone (HGH), also referred to as somatropin or recombinant human growth hormone, is a therapeutically manufactured version of the naturally occurring growth hormone produced by the pituitary gland. GH plays an important role in childhood growth, bone development, muscle formation, and metabolism, with many of its effects mediated through insulin-like growth factor 1 (IGF-1). Growth hormone deficiency (GHD) can occur during childhood or adulthood and may result from congenital conditions, pituitary disorders, tumors, surgery, radiation, or other structural or functional abnormalities. Among children evaluated for short stature, GHD is considered relatively uncommon.

The commercial market is centered on prescription-based hormone replacement therapies, with treatment traditionally delivered through subcutaneous injections. Conventional daily injections remain important, while longer-acting formulations administered less frequently are creating opportunities for improved convenience and treatment adherence. Clinical guidelines emphasize appropriate diagnosis before treatment, with stimulation testing generally used when GHD is suspected. For adults with confirmed deficiency and no contraindications, GH replacement may provide benefits involving body composition, exercise capacity, skeletal health, and quality of life. Treatment decisions and dosing require individualized medical supervision.

Market dynamics are therefore influenced by diagnostic rates, pediatric and adult endocrinology capacity, reimbursement, treatment affordability, physician awareness, product innovation, and patient adherence. Developed healthcare systems generally have stronger access to specialized diagnosis and prescription therapies, whereas emerging markets can present substantial unmet needs because of affordability and limited specialist availability. Competition is also shifting from conventional daily products toward differentiated delivery systems, including long-acting GH. At the same time, regulatory controls remain important because HGH is a prescription medicine and its non-medical use for bodybuilding or performance enhancement is not an appropriate therapeutic indication.

Recent Developments in Human Growth Hormone Market

• April 2026: Anhui Anke Biotechnology (Group) Co., Ltd. advanced its long-acting growth hormone program by holding a Phase III investigator meeting in Hefei for Somatropin-Fc Fusion Protein Injection. The clinical milestone marks further progress for AnkeBio’s weekly growth hormone candidate and reinforces the company’s position in the increasingly competitive long-acting growth hormone market. The development also highlights the industry’s shift toward less frequent dosing as companies seek to differentiate from conventional daily somatropin therapies.
• February 2026: Novo Nordisk announced that the U.S. FDA approved Sogroya (somapacitan-beco) for three additional pediatric indications: idiopathic short stature, short stature in children born small for gestational age who have not achieved catch-up growth by age two, and growth failure associated with Noonan syndrome. The expanded indication set broadens Sogroya’s potential pediatric patient population and further strengthens Novo Nordisk’s lifecycle strategy for its once-weekly growth hormone therapy. The broader label also enhances Sogroya’s competitive positioning against daily somatropin products and other emerging long-acting growth hormone candidates.

Growth Drivers for the Human Growth Hormone (HGH) Market

Rising Diagnosis of Growth Disorders

One of the principal growth drivers for the HGH Market is increasing recognition and diagnosis of growth-related disorders. Pediatric growth monitoring, improved access to endocrinologists, better use of growth charts, laboratory testing, imaging, and stimulation testing can help identify children and adults who may require further evaluation for GHD. The Endocrine Society identifies growth failure as an important clinical sign in children and recommends appropriate diagnostic evaluation rather than relying on a single GH measurement.

Greater awareness among parents, primary-care physicians, pediatricians, and specialists can also encourage earlier referrals. Earlier identification may improve treatment opportunities because GH therapy is most effective when appropriately diagnosed and initiated during the relevant growth period. In adults, recognition of acquired GHD associated with pituitary disease, surgery, irradiation, or other conditions can expand the addressable patient population. Consequently, stronger diagnostic infrastructure and awareness can increase the number of patients entering specialist treatment pathways, supporting long-term demand for prescription HGH products.

Shift Toward Long-Acting Growth Hormone

Product innovation and reduced treatment burden represent another important growth opportunity. Traditional GH therapy commonly requires frequent subcutaneous administration, which can create challenges for children and adults who need long-term treatment. The development and availability of sustained-release and longer-acting GH therapies are changing the competitive landscape by offering less frequent dosing options. The Endocrine Society notes that sustained-release GH administered weekly has become available alongside conventional daily treatment.

Longer dosing intervals can potentially improve convenience and help address adherence challenges associated with repeated injections. This creates opportunities for pharmaceutical companies to differentiate products through delivery technology, dosing frequency, patient-support programs, and device design. Competition is consequently moving beyond the hormone molecule itself toward formulation technology, injection systems, adherence support, and patient experience. As healthcare providers increasingly evaluate treatment effectiveness alongside convenience and persistence, long-acting products may gain importance within the overall HGH market, particularly in developed healthcare systems with greater access to newer therapies.

Expansion of Specialized Endocrine Care

Expansion of specialized endocrinology services and multidisciplinary healthcare infrastructure provides another foundation for HGH market development. GHD diagnosis and management can require pediatric or adult endocrinologists, laboratory testing, growth monitoring, imaging, and long-term follow-up. As healthcare systems strengthen specialist services and referral networks, more patients with suspected endocrine disorders can move from initial assessment toward definitive diagnosis and treatment.

Improved access is particularly relevant in emerging economies where specialist availability and diagnostic infrastructure may historically have been concentrated in major cities. Growth in private hospitals, specialty clinics, diagnostic laboratories, and health insurance coverage can gradually increase access to hormone replacement therapies. Digital health and telemedicine may further support specialist consultations and ongoing monitoring, although prescription treatment remains dependent on appropriate clinical evaluation. The resulting market opportunity is not limited to drug sales: it also encompasses diagnostic services, injection devices, monitoring, patient assistance, pharmacy distribution, and follow-up care associated with long-term GH therapy.

Challenges in the Human Growth Hormone (HGH) Market

High Treatment Cost and Reimbursement Constraints

A major challenge for the HGH Market is the relatively high cost associated with long-term hormone replacement therapy. Treatment can extend over several years, particularly for children with confirmed GHD, making affordability and reimbursement important factors in treatment continuation. The economic burden can include the medicine itself, injection devices, specialist consultations, laboratory monitoring, and periodic assessments.

Access is therefore highly dependent on national reimbursement policies, insurance coverage, eligibility criteria, and household income. In markets where reimbursement is limited, physicians and families may face difficult decisions regarding initiation or continuation of treatment. Adult GHD can also remain underdiagnosed or undertreated. Research presented by the Endocrine Society has highlighted low treatment rates among adults with diagnosed GHD in U.S. insurance populations, illustrating that diagnosis alone does not guarantee access to therapy.

Complex Diagnosis and Treatment Monitoring

The second major challenge is the complexity of diagnosis and long-term monitoring. Growth hormone deficiency cannot always be identified through a simple measurement because GH secretion varies substantially. Clinical guidelines recommend stimulation testing in patients with suspected GHD, while treatment requires individualized dosing and regular monitoring.

This creates several barriers to market expansion, particularly in regions with limited endocrine specialists, diagnostic laboratories, or access to appropriate testing. Misdiagnosis can also lead to inappropriate treatment, while inconsistent follow-up may affect adherence and clinical outcomes. For children, monitoring may involve growth response, IGF-1 levels, and bone-age assessment. Adults may require assessment of metabolic and other health parameters. These requirements increase the complexity of the treatment pathway and can limit adoption where healthcare infrastructure is insufficient. Pharmaceutical companies therefore increasingly compete through patient-support programs, monitoring services, educational initiatives, and simplified delivery technologies.

United States Human Growth Hormone Market

The United States represents a major HGH market because of its advanced healthcare infrastructure, established endocrinology network, extensive pharmaceutical industry, and relatively sophisticated diagnostic capabilities. Demand is supported by treatment of confirmed pediatric and adult GHD and other approved indications. The U.S. market also has strong pharmaceutical competition, with manufacturers investing in recombinant GH products, long-acting formulations, injection devices, and patient-support programs.

However, access is influenced by insurance coverage, prior authorization, formulary restrictions, and treatment costs. The adult segment presents an important opportunity because GHD can remain undertreated despite recognized clinical consequences. Research presented by the Endocrine Society found relatively low somatropin treatment rates among adults with diagnosed GHD in certain U.S. insurance populations. Continued innovation in dosing frequency and delivery systems is expected to shape competition, while regulatory oversight limits inappropriate non-medical use.

Germany Human Growth Hormone Market

Germany has a well-developed healthcare system supported by specialist medical care, statutory health insurance, pediatric services, and pharmaceutical infrastructure, creating favorable conditions for clinically indicated HGH therapy. Demand is concentrated around diagnosed endocrine disorders, particularly pediatric GHD and selected approved growth-related indications. The presence of specialized hospitals and endocrinology centers supports diagnosis, treatment initiation, and long-term monitoring.

The German market is nevertheless shaped by healthcare reimbursement, clinical guidelines, cost-effectiveness considerations, and prescription controls. Pharmaceutical companies compete through product quality, formulation innovation, injection technology, and treatment convenience. Long-acting GH formulations may create additional opportunities by reducing injection frequency and addressing treatment burden. Germany's mature healthcare environment also means that market expansion is likely to depend more on improved diagnosis, eligible patient identification, treatment persistence, and product differentiation than on basic healthcare-access expansion. Clinical evidence and physician confidence therefore remain central to commercial adoption.

India Human Growth Hormone Market

India represents an emerging opportunity for the HGH Market, supported by a large population, expanding private healthcare infrastructure, increasing awareness of pediatric endocrine disorders, and growing availability of specialist medical services. Demand is primarily associated with clinically diagnosed growth disorders and hormone deficiencies, while access remains concentrated in metropolitan areas and specialist centers.

The market faces significant affordability and healthcare-access challenges, particularly because long-term GH therapy can impose substantial costs on families. Availability of pediatric endocrinologists and specialized diagnostic facilities also varies considerably between urban and rural regions. At the same time, increasing private hospitals, diagnostic laboratories, health insurance penetration, and medical awareness can improve patient identification and treatment access. India's regulatory environment for medicines, including imported and domestically marketed products, is overseen through national pharmaceutical authorities such as the Central Drugs Standard Control Organization (CDSCO). Future growth is therefore likely to depend on affordability, specialist expansion, diagnosis, and broader access to evidence-based endocrine care.

UAE Human Growth Hormone Market

The UAE HGH Market benefits from a relatively advanced healthcare infrastructure, high healthcare expenditure, private-sector participation, and growing availability of specialist medical services. Major urban healthcare centers provide access to endocrinologists, pediatric specialists, diagnostic laboratories, and advanced pharmaceutical therapies. The country's expatriate population and development of specialized healthcare facilities also contribute to demand for sophisticated treatments.

Growth is nevertheless dependent on clinical eligibility, regulatory compliance, insurance coverage, and treatment affordability. HGH is a prescription therapy, making physician diagnosis and appropriate monitoring essential. The UAE maintains a formal government framework covering healthcare legislation and pharmaceutical regulation. Ministry of Health and Prevention The market provides opportunities for multinational pharmaceutical companies offering recombinant and long-acting GH therapies, particularly where advanced healthcare providers prioritize treatment convenience and adherence. Increasing medical specialization and demand for high-quality healthcare services can support market development, while strict controls help limit inappropriate or non-medical use.

Growth Hormone (GH) Deficiency Market

The Growth Hormone Deficiency Market represents the core therapeutic segment of the broader HGH industry. GHD can affect children and adults, with causes ranging from congenital conditions to pituitary disorders, tumors, surgery, irradiation, and other acquired conditions. In children, impaired growth and short stature are important clinical indicators, while adults with severe GHD may experience changes in body composition, muscle strength, energy levels, lipid profiles, and bone health. 

Treatment generally involves prescription recombinant GH, with conventional daily injections remaining established and longer-acting therapies expanding the available options. Diagnosis requires appropriate clinical assessment and, in many suspected cases, stimulation testing. Market expansion therefore depends on diagnostic awareness, specialist availability, reimbursement, treatment adherence, and pharmaceutical innovation. Although GHD is a relatively rare disorder, its long treatment duration can create significant cumulative demand for GH therapies and related monitoring services.

Hospital Pharmacy Market

Hospital pharmacies represent an important distribution and treatment-support channel for HGH products, particularly during diagnosis, treatment initiation, specialist supervision, and management of complex endocrine conditions. Hospitals provide access to pediatric endocrinologists, adult endocrinologists, laboratories, imaging facilities, and multidisciplinary teams, making them important points within the patient journey.

The channel is particularly relevant for newly diagnosed patients who require treatment planning and education before continuing therapy at home. Hospital pharmacies can support prescription verification, product storage, dispensing, patient counseling, and coordination with specialist departments. In advanced healthcare systems, hospital procurement may also be influenced by formulary decisions, reimbursement arrangements, institutional purchasing policies, and comparative evaluation of competing GH products. As long-acting formulations become more available, hospital specialists can play an important role in selecting therapies based on clinical suitability, dosing frequency, patient preference, and treatment persistence. Consequently, hospital pharmacies remain strategically important even when subsequent prescriptions are fulfilled through retail or specialty pharmacy channels.

Oral Market

The oral HGH segment represents an emerging and technologically challenging area within the broader growth-hormone landscape. Unlike conventional HGH therapy, which is administered subcutaneously, oral delivery seeks to provide the hormone through a more convenient route. However, GH is a peptide hormone, creating substantial formulation and absorption challenges for oral administration because biological molecules can be degraded within the gastrointestinal tract and may have limited systemic bioavailability.

Consequently, injectable therapies remain the established route for clinically indicated GH replacement, while research into alternative delivery technologies focuses on improving convenience without compromising therapeutic exposure. The commercial opportunity for oral or non-injectable GH would depend on demonstrating reliable absorption, consistent dosing, safety, efficacy, and regulatory acceptability. If these barriers are successfully addressed, oral delivery could potentially reduce injection burden and broaden patient acceptance. Until then, the segment should be viewed as an emerging technology opportunity rather than an established mainstream HGH delivery channel.

Research Methodology of Global Human Growth Hormone (HGH) Market

The Global Human Growth Hormone (HGH) Market was estimated using a combination of bottom-up and top-down approaches, secondary research, company-level revenue analysis, patient-based estimation, treatment-volume analysis, pricing analysis, and data triangulation. The methodology covered pharmaceutical human growth hormone products used for approved therapeutic indications and considered differences in treatment adoption, pricing, reimbursement, and healthcare access across countries.

1. Market Definition and Scope

• The estimation process began by defining the scope of the Global Human Growth Hormone (HGH) Market.
• The analysis included recombinant human growth hormone products used for medically approved growth hormone-related conditions.
• The same market definition was maintained across all countries to ensure comparability.

2. Secondary Research

• Secondary research was conducted using information from:
  • Regulatory authorities
  • Government health agencies
  • Pharmaceutical companies
  • Medical associations
  • Clinical publications
  • Annual reports
  • Investor presentations
  • Product labels
  • Drug databases
  • Healthcare statistics
• The research focused on gathering information related to:
  • Growth hormone deficiency prevalence
  • Diagnosed patient populations
  • Number of patients receiving HGH therapy
  • Treatment eligibility
  • Prescription volumes
  • Product approvals
  • Product sales
  • Treatment prices
  • Reimbursement policies
  • Market access
  • Clinical guidelines
• These sources were used to establish the historical market structure and identify the major companies and products contributing to HGH revenues.

3. Bottom-Up Market Estimation

• The bottom-up approach was used to construct the market from the individual country, company, product, and indication levels.
• Major HGH manufacturers were identified, and their relevant product revenues were collected from annual reports, financial statements, investor presentations, product disclosures, and other publicly available sources.
• Where product-specific revenue was available, it was directly incorporated into the calculation.
• Where companies reported broader endocrine or pharmaceutical revenues, the HGH-related portion was estimated using:
  • Product-level sales
  • Geographic contribution
  • Prescription information
  • Other supporting indicators
• The basic calculation was:
  • HGH Market Value = Number of Treated Patients × Average Annual HGH Treatment Cost
• Where treatment-volume information was available, the calculation was also represented as:
  • HGH Market Value = Treatment Volume × Average Realized Selling Price
• The estimates were then aggregated across products, indications, companies, and countries.

4. Patient-Based Estimation

• A patient-based approach was used in countries where company-level revenue information was limited.
• The estimation began with the population affected by conditions requiring HGH therapy.
• The population was then filtered according to:
  • Eligible Population → Diagnosed Population → Treatment-Eligible Population → Treated Population
• The number of treated patients was multiplied by the average annual cost of HGH therapy.
• The calculation was adjusted for differences in:
  • Patient age
  • Treatment dosage
  • Treatment duration
  • Disease severity
  • Product selection
  • Treatment adherence
  • Healthcare access
  • Reimbursement
• This approach helped estimate markets where direct product sales data were unavailable.

5. Treatment Volume Analysis

• HGH treatment volumes were estimated by assessing:
  • Prescription information
  • Patient numbers
  • Dosage requirements
  • Treatment frequency
  • Treatment duration
• For pediatric patients, the analysis considered the typical duration of treatment and the number of patients receiving therapy during the relevant year.
• For adult patients, the calculation considered replacement therapy requirements and the applicable treatment population.
• Where available, prescription volumes and pharmaceutical sales were used to validate the patient-based calculations.

6. Pricing Analysis

• HGH pricing was analyzed at the country level because treatment costs varied significantly between markets.
• The analysis considered:
  • List prices
  • Wholesale prices
  • Hospital procurement prices
  • Pharmacy prices
  • Reimbursed prices
  • Average selling prices
  • Discounts and rebates
  • Branded product pricing
  • Biosimilar pricing
• For patient-based estimation, the annual treatment cost was calculated by considering the dosage requirement and treatment duration rather than simply applying the price of a single HGH package.
• A simplified calculation was:
  • Annual Treatment Cost = Average Daily Dose × Treatment Days × Realized Price per Unit
• The resulting treatment cost was multiplied by the number of treated patients.

7. Company Revenue Analysis

• The revenues of major HGH manufacturers were analyzed to establish the competitive market structure.
• Company research included:
  • HGH product portfolios
  • Product-level sales
  • Geographic revenues
  • Prescription products
  • New product launches
  • Regulatory approvals
  • Pipeline developments
  • Licensing agreements
  • Strategic partnerships
  • Acquisitions
  • Biosimilar developments
• Where a company marketed HGH products under multiple brands or formulations, revenues were allocated according to the defined product scope.
• Company revenues were then compared with country-level and global market estimates to identify potential inconsistencies.

8. Application-Based Estimation

• The market was also estimated according to major therapeutic indications.
• The analysis assessed the number of patients treated for:
  • Growth hormone deficiency
  • Turner syndrome
  • Idiopathic short stature
  • Prader-Willi syndrome
  • Small for Gestational Age
  • Other approved indications
• For each indication, the number of treated patients and corresponding treatment cost were estimated.
• The calculation was:
  • Indication Market Value = Treated Patients for Indication × Average Annual Treatment Cost
• The individual indication values were then aggregated to calculate the overall HGH market.

9. Top-Down Market Estimation

• A top-down approach was used to validate the bottom-up results.
• The calculation began with broader pharmaceutical or endocrine-treatment expenditures for each country.
• The proportion attributable to HGH therapy was then estimated using factors such as:
  • Number of eligible patients
  • Treatment penetration
  • Prescription rates
  • HGH adoption
  • Healthcare expenditure
  • Availability of approved HGH products
  • Reimbursement
  • Physician awareness
• The calculation was broadly represented as:
  • Relevant Pharmaceutical Market × HGH Treatment Share = Estimated HGH Market
• The resulting value was compared with the bottom-up estimate.

10. Geographic Market Estimation

• The Global HGH Market was estimated separately for major regions and countries.
• For each geographic market, the analysis considered:
  • Population size
  • Birth rates and pediatric population
  • Disease prevalence
  • Diagnosis rates
  • Healthcare infrastructure
  • Endocrinologist availability
  • Treatment penetration
  • Pharmaceutical expenditure
  • Insurance coverage
  • Government reimbursement
  • Product availability
  • Local pricing
  • Regulatory environment
• Country-level values were subsequently aggregated to determine regional and global market sizes.

11. Product-Level Analysis

• Individual HGH products were mapped across major countries.
• For each product, information was collected regarding:
  • Manufacturer
  • Brand name
  • Formulation
  • Dosage strength
  • Approved indications
  • Patient population
  • Regulatory status
  • Pricing
  • Sales
  • Geographic availability
• This product-level mapping helped determine the contribution of individual therapies to the overall market and reduced the possibility of double counting.

12. Biosimilar and Competitive Product Analysis

• The impact of biosimilar HGH products was incorporated into the estimation where applicable.
• The analysis considered:
  • Biosimilar approvals
  • Market entry
  • Price differences
  • Physician adoption
  • Patient switching
  • Reimbursement
  • Hospital procurement
  • Competition with established brands
• The entry of lower-priced products was incorporated into pricing and revenue assumptions rather than assuming that historical branded-product prices remained unchanged throughout the forecast period.

13. Regulatory and Reimbursement Assessment

• Regulatory approvals and reimbursement policies were reviewed because HGH therapy was highly dependent on medical eligibility and healthcare coverage.
• The assessment included:
  • Approved indications
  • Prescription requirements
  • Eligibility criteria
  • Insurance coverage
  • Government reimbursement
  • Prior authorization
  • Specialty pharmacy requirements
  • Treatment guidelines
• Differences in reimbursement and access were incorporated into country-level treatment penetration assumptions.

14. Data Triangulation

• The results from different estimation methods were compared through data triangulation.
• Three major estimates were considered:
  • Bottom-Up Estimate
    • Product and company revenues
    • Treatment volumes
    • Patient-based calculations
  • Top-Down Estimate
    • Relevant pharmaceutical market
    • Estimated HGH contribution
  • Secondary Validation
    • Government statistics
    • Regulatory databases
    • Company disclosures
    • Medical and industry publications
• Where differences were identified, the underlying assumptions were reviewed using additional company disclosures, healthcare statistics, treatment data, and expert feedback.

15. Forecast Market Estimation

• After determining the base-year market size, the forecast was developed by analyzing factors expected to influence HGH demand.
• These included:
  • Increasing diagnosis of growth hormone deficiency
  • Improved access to endocrine care
  • Greater awareness of growth-related disorders
  • Expansion of HGH treatment availability
  • Development of long-acting HGH formulations
  • Product approvals
  • Expansion of specialty pharmacies
  • Changes in reimbursement
  • Adoption of biosimilar products
  • Improvements in diagnosis
  • Expansion of healthcare infrastructure
  • Growth in emerging markets
• The expected effect of each factor was incorporated into:
  • Patient numbers
  • Treatment penetration
  • Treatment costs
  • Product revenues

16. Final Global Market Calculation

• The final Global Human Growth Hormone (HGH) Market size was established after reconciling:
  • Product-level revenues
  • Company revenues
  • Treated patient populations
  • Treatment volumes
  • Pricing information
  • Indication-level estimates
  • Top-down calculations
  • Secondary research findings
• This methodology provided a structured basis for estimating the Global Human Growth Hormone (HGH) Market across:
  • Treatment indications
  • Patient groups
  • Products
  • Countries
  • Regions
  • Forecast years
• The methodology also maintained consistency across market segments while minimizing the risk of double counting.

Market Segmentation

Application

• Growth Hormone (GH) Deficiency
• Turner Syndrome
• Idiopathic Short Stature (ISS)
• Prader-Willi Syndrome (PWS)
• Small for Gestational Age
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Route of Administration

• Intravenous
• Intramuscular
• Subcutaneous
• Oral

Countries

North America

• United States
• Canada

Europe

• France
• Germany
• Italy
• Spain
• United Kingdom
• Belgium
• Netherlands
• Turkey

Asia Pacific

• China
• Japan
• India
• South Korea
• Thailand
• Malaysia
• Indonesia
• Australia
• New Zealand

Latin America

• Brazil
• Mexico
• Argentina

Middle East & Africa

• Saudi Arabia
• UAE
• South Africa

All Key Players have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Key Players Analysis

1. Eli Lilly and Company
2. EMD Serono Inc.
3. F. Hoffmann-La Roche AG
4. Ferring B.V.
5. Genentech Inc.
6. Ipsen
7. Merck KGaA
8. Novartis AG
9. Novo Nordisk
10. Pfizer Inc.

Report Details: